Doctor Strange in the Multiverse of Madness vs. Avengers: Endgame: Box Office & Theatrical Economics Faceoff

Doctor Strange in the Multiverse of Madness vs. Avengers: Endgame: Theatrical Economics, P&A Recoupment & Studio Return

In evaluating the commercial faceoff between Doctor Strange in the Multiverse of Madness and Avengers: Endgame, worldwide ticket receipts provide only the top-line baseline of cinematic profitability. Avengers: Endgame captured higher aggregate worldwide box office gross of $2.80 Billion, establishing a $1843 million gross advantage over Doctor Strange in the Multiverse of Madness's $956 Million.

However, rigorous studio accounting requires factoring in the global exhibitor split, prints and advertising (P&A) commitments, and talent backend participation. Applying the standard Hollywood blended 50% distributor rental take, Avengers: Endgame converted its theatrical receipts into approximately $1399.5 million in studio rentals, providing the vital cash flow necessary to offset its $356M production budget and global marketing campaign.

From a pure capital efficiency standpoint, Avengers: Endgame achieved superior return on invested capital, delivering an impressive 7.86x recoupment multiple against its initial production budget, compared to 4.78x for Doctor Strange in the Multiverse of Madness. In critical evaluation, Avengers: Endgame leads the artistic consensus with a Certified Fresh score of 96%, demonstrating that commercial velocity and critical standing can align effectively in modern franchise distribution.

Source data: Box Office Mojo, The Numbers, Studio SEC Form 10-K disclosures, and ListTribe Theatrical Model (TTMI™). Verified September 2026.